INTEGRATE-ATMP

The application of the app is being tested and evaluated as part of the INTEGRATE ATMP project, which is funded by the Innovation Fund of the Joint Federal Committee. The app enables patients to communicate directly with their treatment centers as part of the application and aftercare of novel gene and cell therapies. Treated patients can collect data about their satisfaction with the treatment and their health-related quality of life from home and transmit it directly to their practitioners. Treatment results and a standardized treatment plan are visualized and automatically transmitted pseudonymously to a connected gene and cell therapy registry. In the near future, medical documents and other information will also be able to be exchanged end-to-end encrypted and transmitted to the specialized treatment centers both by the patients themselves and by practicing doctors. The app is connected to a telemedicine platform on the practitioner side, from which the treatment teams can communicate directly and securely with patients. The app is currently only available to treated patients who are invited to participate by their treatment centers as part of the use of a gene and cell therapy product. 25 German treatment centers are currently taking part in the project. The consortium is managed by the Heidelberg University Hospital.